John M. Mariadason
Affiliations: | Ludwig Institute for Cancer Research, San Diego, CA, United States |
Google:
"John Mariadason"Mean distance: (not calculated yet)
Children
Sign in to add trainee| Anderly C. Chueh | post-doc | 2009-2013 | Ludwig Institute for Cancer Research |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Thilakasiri P, O'Keefe RN, To SQ, et al. (2023) Mechanisms of cellular crosstalk in the gastric tumor microenvironment are mediated by YAP1 and STAT3. Life Science Alliance. 7 |
| Chüeh AC, Tse JWT, Dickinson M, et al. (2023) Correction: ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors Across Tumor Types. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 29: 3826 |
| Harris TJ, Liao Y, Shi W, et al. (2023) Induction of endoplasmic reticulum stress is associated with the anti-tumor activity of monepantel across cancer types. Cancer Medicine |
| Esmaeilniakooshkghazi A, Pham E, George SP, et al. (2023) In colon cancer cells fascin1 regulates adherens junction remodeling. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 37: e22786 |
| Tögel L, Nightingale R, Wu R, et al. (2023) Author Correction: DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis. Scientific Reports. 13: 2422 |
| Jenkins LJ, Luk IY, Fairlie WD, et al. (2022) Genotype-tailored ERK/MAPK pathway and HDAC inhibition rewires the apoptotic rheostat to trigger colorectal cancer cell death. Molecular Cancer Therapeutics |
| Luk IY, Jenkins LJ, Schoffer KL, et al. (2022) Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression. Cell Death and Differentiation |
| Weickhardt AJ, Lau DK, Hodgson-Garms M, et al. (2022) Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer. Bmc Cancer. 22: 478 |
| Chionh F, Gebski V, Al-Obaidi SJ, et al. (2022) VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer. Scientific Reports. 12: 1238 |
| Arulananda S, O'Brien M, Evangelista M, et al. (2021) A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. Cell Death Discovery. 7: 122 |